Status:

RECRUITING

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

Lead Sponsor:

Coordinación de Investigación en Salud, Mexico

Conditions:

Ductal Breast Carcinoma in Situ

Invasive Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to det...

Detailed Description

PRIMARY OBJECTIVE: I. Compare the effectiveness of hypofractionated radiotherapy (1 week) with standard treatment (3.1 weeks) in the local control of breast cancer treated with conservative surgery. ...

Eligibility Criteria

Inclusion

  • Patients diagnosed by histopathological report of ductal carcinoma in situ (DCIS) or invasive breast carcinoma.
  • Treated with breast-conserving surgery and stage pT1-2 pN0 M0.
  • Over 18 years.
  • Patients who sign informed consent for research study.

Exclusion

  • Positive nodes.
  • Clinical or pathological stage T3-T4.
  • History of previous irradiation.
  • Postoperative positive margin.

Key Trial Info

Start Date :

April 26 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2026

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT05318274

Start Date

April 26 2021

End Date

June 30 2026

Last Update

November 9 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Unidad Medica de Alta Especialidad

Mérida, Yucatán, Mexico, 97150